Nicole B Gidaya1, Brian K Lee2, Igor Burstyn2, Yvonne Michael3, Craig J Newschaffer2, Erik L Mortensen4. 1. Drexel University School of Public Health, and ngidaya@gmail.com. 2. Drexel University School of Public Health, and A.J. Drexel Autism Institute, Drexel University, Philadelphia, Pennsylvania; and. 3. Drexel University School of Public Health, and. 4. Institute of Public Health and Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVES: The purpose of this study was to investigate associations between use of β-2-adrenergic receptor (B2AR) agonist drugs during pregnancy and risk for autism spectrum disorders (ASD). METHODS: A case-control study was conducted by using Denmark's health and population registers. Among children born between 1997 and 2006, 5200 cases with ASD admission diagnoses and 52 000 controls without ASD were identified and individually matched on month and year of birth. Conditional logistic regression models were used to estimate odds ratios (OR) and confidence intervals (CI) for any B2AR agonist exposure during pregnancy, preconception, and by trimester. RESULTS: In total, 3.7% of cases and 2.9% of controls were exposed to B2ARs during pregnancy. Use of B2ARs during pregnancy was associated with increased risk of ASD, even after adjustment for maternal asthma and other covariates (OR: 1.3, 95% CI: 1.1-1.5). The elevated risk was observed with use of B2AR during preconception (OR: 1.3, 95% CI: 1.0-1.6), first trimester (OR: 1.3, 95% CI: 1.1-1.5), second trimester (OR: 1.5, 95% CI: 1.1-1.7), and the third trimester (OR: 1.4, 95% CI: 1.1-1.7). There was some evidence that longer B2AR within-pregnancy use was associated with the increased risk. CONCLUSIONS: B2AR agonist exposure during pregnancy may be associated with an increased risk for ASD. If the effect is real, any intervention must be balanced against benefits of indicated medication use by pregnant women.
OBJECTIVES: The purpose of this study was to investigate associations between use of β-2-adrenergic receptor (B2AR) agonist drugs during pregnancy and risk for autism spectrum disorders (ASD). METHODS: A case-control study was conducted by using Denmark's health and population registers. Among children born between 1997 and 2006, 5200 cases with ASD admission diagnoses and 52 000 controls without ASD were identified and individually matched on month and year of birth. Conditional logistic regression models were used to estimate odds ratios (OR) and confidence intervals (CI) for any B2AR agonist exposure during pregnancy, preconception, and by trimester. RESULTS: In total, 3.7% of cases and 2.9% of controls were exposed to B2ARs during pregnancy. Use of B2ARs during pregnancy was associated with increased risk of ASD, even after adjustment for maternal asthma and other covariates (OR: 1.3, 95% CI: 1.1-1.5). The elevated risk was observed with use of B2AR during preconception (OR: 1.3, 95% CI: 1.0-1.6), first trimester (OR: 1.3, 95% CI: 1.1-1.5), second trimester (OR: 1.5, 95% CI: 1.1-1.7), and the third trimester (OR: 1.4, 95% CI: 1.1-1.7). There was some evidence that longer B2AR within-pregnancy use was associated with the increased risk. CONCLUSIONS:B2AR agonist exposure during pregnancy may be associated with an increased risk for ASD. If the effect is real, any intervention must be balanced against benefits of indicated medication use by pregnant women.
Authors: Lisa A Croen; Yinge Qian; Paul Ashwood; Julie L Daniels; Daniele Fallin; Diana Schendel; Laura A Schieve; Alison B Singer; Ousseny Zerbo Journal: Autism Res Date: 2018-08-10 Impact factor: 5.216
Authors: María Victoria Bariani; Fernando Correa; Emma Leishman; Ana Paula Domínguez Rubio; Andreína Arias; Aníbal Stern; Heather B Bradshaw; Ana María Franchi Journal: Mol Hum Reprod Date: 2017-08-01 Impact factor: 4.025
Authors: Destanie R Rose; Houa Yang; Milo Careaga; Kathy Angkustsiri; Judy Van de Water; Paul Ashwood Journal: Brain Behav Immun Health Date: 2020-01-26
Authors: Vanja Mandic-Maravic; Marija Mitkovic-Voncina; Marija Pljesa-Ercegovac; Ana Savic-Radojevic; Miroslav Djordjevic; Tatjana Pekmezovic; Roberto Grujicic; Marko Ercegovac; Tatjana Simic; Dusica Lecic-Tosevski; Milica Pejovic-Milovancevic Journal: Front Psychiatry Date: 2019-09-25 Impact factor: 4.157